Heart Failure and Reduced Ejection Fraction

Cardiovascular
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
LCZ696Phase 41 trial
Active Trials
NCT02874794Completed465Est. Jan 2019
Impulse Dynamics
Impulse DynamicsNY - Pearl River
1 program
Cardiac Contractility ModulationN/A1 trial
Active Trials
NCT07209098RecruitingEst. Apr 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisLCZ696
Impulse DynamicsCardiac Contractility Modulation

Clinical Trials (2)

Total enrollment: 465 patients across 2 trials

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Start: Aug 2016Est. completion: Jan 2019465 patients
Phase 4Completed
NCT07209098Impulse DynamicsCardiac Contractility Modulation

Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure

Start: Nov 2025Est. completion: Apr 2031
N/ARecruiting

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 465 patients
2 companies competing in this space